A double-blind sham-controlled phase 1 clinical trial of tDCS of the dorsolateral prefrontal cortex in cocaine inpatients: craving, sleepiness, and contemplation to change

Pierre-Olivier GAUDREAULT, PhD,[1] Akarsh SHARMA, MS,[1] Abhishek DATTA, PhD,[2] Ester M. NAKAMURA-PALACIOS, MD, PhD,[3] Sarah KING, BSc, [1] Pias MALAKER, MSc, [1] Ariella WAGNER, MSc, [1] Devarshi VASA, [1] Muhammad A. PARVAZ, PhD,[1] Lucas C. PARRA, PhD,[4] Nelly ALIA-KLEIN, PhD,[1] Rita Z. GOLDSTEIN, PhD[1]

1. Psychiatry and Neuroscience Department, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
2. Soterix Medical Inc. New York City, NY, USA.
3. Program of Post-Graduation in Physiological Sciences, Federal University of Espirito Santo, Vitoria-ES, Brazil.
4. Biomedical Engineering Department, City College of New York, New York City, NY, USA.

Running Title (50 characters including spaces max): tDCS of the dlPFC in cocaine inpatients

Word Count manuscript: 5847
Word Count abstract: 250

Number of pages: 38
Number of figures: 5
Number of tables: 3

Corresponding author:
Rita Z. Goldstein, PhD
Professor
Department of Psychiatry (primary) and Department of Neuroscience (secondary)
Chief, Neuropsychoimaging of Addiction and Related Conditions (NARC) Research Program
Icahn School of Medicine
Gustave L. Levy Place, Box 1230
New York, NY 10029
Tel: 212-659-8886
rita.goldstein@mssm.edu

Abstract

Impaired inhibitory control accompanied by enhanced salience attributed to drug-related cues, both dorsolateral prefrontal cortex (dlPFC) functions, are hallmarks of drug addiction, contributing to worse symptomatology including craving. dlPFC modulation with transcranial direct current stimulation (tDCS) showed craving reduction in inpatients with cocaine use disorder (CUD). Our study aimed at assessing feasibility of a longer tDCS protocol in CUD (15 vs. the common five/10 sessions), and replicability of previous results.

In a randomized double-blind sham-controlled protocol, 17 inpatients were assigned to either a real-tDCS (right anodal/left cathodal) or a sham-tDCS condition, for 15 sessions. Primary outcome measures were self-reported craving, anxiety, depression, and quality of life. Secondary measures included sleepiness, readiness to change drug use, and affect. We also assessed cognitive function including impulsivity.

An 82% retention rate demonstrated feasibility. Partially supporting previous results, there was a trend for self-reported craving to decrease in the real-tDCS group more than the sham group, an effect that would reach significance with 15 subjects per group. Quality of life and impulsivity improved over time of treatment in both groups. Significant group × time interactions showed improvements after treatment only in the real-tDCS group for daytime sleepiness and readiness to change drug use. One-month follow-up suggested transient effects of tDCS on sleepiness and craving.

This study suggests that more subjects are needed to show a unique effect of real-tDCS on craving and to examine the duration of effect. Increased vigilance and motivation to change in the real-tDCS group suggest fortification of dlPFC-supported executive functions.

Keywords: Transcranial Direct Current Stimulation (tDCS), Cocaine use disorder, Drug

addiction, Dorsolateral prefrontal cortex, Self-reported craving.

Introduction

Drug addiction is a chronic brain disorder characterized by a relapsing cycle of compulsive drug seeking and using followed by withdrawal and craving that repeat despite harmful consequences (Volkow & Fowler, 2000). The underlying mechanisms encompass impairments in prefrontal cortex-mediated functions that include reduced inhibitory control of automatic or maladaptive behaviors, as well as the attribution of excessive salience to the drug and drug-related cues at the expense of non-drug related stimuli and cues, in a syndrome referred to as the impaired response inhibition and salience attribution (iRISA; (Goldstein & Volkow, 2002, 2011). Specifically, dysfunction in dorsolateral subregions of the prefrontal cortex (dlPFC), associated with impairments in executive control, is thought to contribute to impulsive, compulsive, inflexible, or stimulus-driven behaviors (Lubman *et al.*, 2004; Simon *et al.*, 2007; Garavan *et al.*, 2008), including craving. Drug craving, the intense subjective urge to use drugs, predicts clinical outcomes such as drug use and the propensity to relapse in drug addicted individuals (Ludwig & Wikler, 1974; Weiss *et al.*, 2003; Paliwal *et al.*, 2008; Chaves *et al.*, 2011). Craving has therefore been considered an important therapeutic target in the treatment of substance use disorders (Tiffany & Wray, 2012; Tiffany *et al.*, 2012). However, as most pharmacological treatments and behavioral therapies for this purpose show inconsistent results (Hennessy *et al.*, 2003; Sofuoglu & Kosten, 2006; Zilverstand *et al.*, 2016; Mellentin *et al.*, 2017; Liu & Li, 2018), reducing craving in drug addiction remains a challenge.

Through the use of magnetic or electric brain stimulation, neuromodulation has recently gained momentum as an adjunct therapy for various psychiatric conditions including bipolar disorder and depression as well as for pain management (Kuo *et al.*, 2014; Rapinesi *et al.*, 2015; Sampaio-Junior *et al.*, 2018). By targeting specific brain regions implicated in addiction such as

the dlPFC, neuromodulation has also been used in drug addicted individuals to reduce craving and maladaptive addiction-related behaviors (see Ekhtiari *et al.*, 2019 for review). A recent meta-analysis of studies using non-invasive brain stimulation over the dlPFC, the medial prefrontal cortex, and the anterior cingulate cortex, showed a specific strong main effect on drug craving in stimulant-addicted individuals (Ma *et al.*, 2019). For instance, repeated sessions of transcranial magnetic stimulation (TMS), which consists of focal electromagnetic pulses that elicit neuronal firing in the targeted region under a coil positioned on the scalp (Hallett, 2007; Wagner *et al.*, 2007; Rossi *et al.*, 2009), showed reductions in subjective craving as well as drug intake when the dlPFC was targeted in cocaine addicted individuals (Bolloni *et al.*, 2016; Rapinesi *et al.*, 2016; Terraneo *et al.*, 2016). A study in young males with cocaine use disorder (CUD) found that even a single session of repetitive TMS had an effect (albeit transient) on reducing craving (Camprodon *et al.*, 2007). Although these studies show promising outcomes, the widespread use of TMS is limited by several factors (e.g., its lack of portability, the expertise required for administration, expense, etc.). As a battery-powered portable device that can be used remotely and repetitively, transcranial direct current stimulation (tDCS) directly applies small amounts of continuous low-intensity electric currents to the scalp in order to facilitate, in a polarity-dependent fashion, cortical excitability through changes in neuronal membrane potentials (Bindman *et al.*, 1964; Nitsche & Paulus, 2000). The repeated use of tDCS specifically targeting the dlPFC either daily or every other day for up to 10 days showed a reduction in subjective self-reported craving (Batista *et al.*, 2015; de Almeida Ramos *et al.*, 2016; Klauss *et al.*, 2018), and a decrease in electrophysiological measures of drug-related cue reactivity (Conti & Nakamura-Palacios, 2014; Conti *et al.*, 2014; Nakamura-Palacios *et al.*, 2016) as well as in risk-taking behaviors (Gorini *et al.*, 2014) in individuals with CUD (studies mostly conducted in Brazil). Recently, a study combining tDCS and positron emission tomography in healthy individuals suggested that repeated tDCS over the dlPFC induced dopamine

release in the ventral striatum, a hub within the reward and motivation network, pointing to a possible putative neurochemical mechanism of such scalp-based brain stimulation (Fonteneau *et al.*, 2018).

The goal of the current Phase 1 clinical trial was therefore to replicate the previous tDCS findings in treatment-seeking individuals with CUD living in an inpatient drug-rehabilitation facility in a northeastern US urban area. Given an ultimate goal of developing a home-based self-administration protocol, a related main aim was to assess the feasibility of administering 15 repeated sessions of tDCS in contrast to the previous shorter tDCS administration protocols. Based on the previous findings (Batista *et al.*, 2015), our main hypothesis was that real-tDCS will be associated with a decrease in the subjective reports of cocaine craving as well as symptoms of anxiety and depression, and with an increase in quality of life measures. In line with the literature, we also assessed the effect of repeated tDCS on secondary outcome measures, including subjective sleep measures (Minichino *et al.*, 2014; Frase *et al.*, 2016; Sheng *et al.*, 2018; Charest *et al.*, 2019), readiness to change (Opsal *et al.*, 2019), and positive and negative affect (Wiegand *et al.*, 2019). Neuropsychological tests measuring verbal fluency (including drug-related fluency as a proxy of cue-reactivity), temporal discounting/impulsivity, and self-reported sensitivity to reinforcement of rewards (Goldstein *et al.*, 2010), were also included for exploratory purposes.

Materials and Methods

Participants

Twenty-nine detoxified and abstinent individuals with CUD between the ages of 18 and 65 years were recruited from, and studied at, an inpatient addiction treatment facility (Samaritan Daytop Village – Jamaica, Queens, NY). Potential participants were identified from rolling

admissions and were screened for the study following a period of detoxification (≥two weeks since

last drug use). All participants met the diagnostic criteria for CUD as corroborated by a

comprehensive diagnostic interview that included the Structured Clinical Interview for *Diagnostic*

and Statistical Manual of Mental Disorders, Fifth Edition (First, 2015) and the Addiction Severity

Index (McLellan *et al.*, 1992) to evaluate lifetime drug use and recency of drug use. Drug use

questionnaires and scales also included the 5-item Severity of Dependence Scale (Foltin, 1999),

the 18-item Cocaine Selective Severity Assessment (Kampman *et al.*, 1998) for withdrawal

symptoms within 24 hours of the interview, and the Cocaine Negative Consequences Checklist

(Michalec *et al.*, 1996). Exclusion criteria were: 1) current or past history of a major neurological

disorder, seizures or a neurodevelopmental disorder; 2) a history of head trauma with loss of

conciousness (for ≥30 minutes); 3) history of Axis I disorders (with the exception of CUD)

associated with psychotic symptoms; 4) medication use with known effects on the central nervous

system within the past 6 months (except psychotropics for symptoms of depression/anxiety/post

traumatic stress disorder); 5) a clinically significant and/or unstable medical illness or infection; 6)

the presence of contraindicated metallic implants or devices that may be affected by electrical

stimulation; and 7) pregnancy or breast feeding in women. All participants provided full written

consent in accordance with both the Icahn School of Medicine at Mount Sinai and the Samaritan

Daytop Village's institutional review boards. This study was registered under Clinical Trials.gov

number NCT03833583.

Of the 29 inpatients with CUD who were consented, one was withdrawn from the study

(due to inability to attend the appointments) (Figure 1). Of the remaining 28 subjects, 17 individuals

qualified for the study (meeting the inclusion/exclusion criteria), completing the pre-treatment

behavioral assessments before being randomly assigned to either the real-tDCS or the sham-tDCS

condition (control group). During the course of treatment, three participants withdrew from the

study, all in the sham-tDCS group (this intriguing difference between the groups in drop-out rate should be further explored with larger samples). They were considered lost to follow-up: two relapsed (after 4 and 9 sessions, respectively) leaving the treatment facility on their own accord; the third participant was transferred to another facility (that did not allow participation in research) after 12 sessions. Of the 14 subjects who completed all 15 tDCS sessions, 12 participants (real-tDCS: N = 7; sham-tDCS: N = 5) attended a one-month follow-up visit (2 participants were not able to attend due to a change in treatment location). All subjects continued taking their prescribed medications throughout the study. The demographic, neuropsychological and drug-related variables of the subjects who completed all 15 tDCS sessions in both groups are presented in Table 1.

Double-Blind Study Procedures

Fourteen participants underwent all 15 sessions of either real-tDCS or sham-tDCS every other day over five weeks. The stimulations were administered using a battery-driven 1×1 (one anode and one cathode) portable tDCS mini-CT device (Soterix Medical, Inc., New York, USA). Two single-use 35 cm^2 sponge electrodes pre-soaked in a saline solution were used with the cathodal electrode placed over the left hemisphere (F3 electrode) and the anodal electrode over the right hemisphere (F4 electrode) targeting the dlPFC. The anodal (positive) and cathodal (negative) nature of the stimulation refers to the polarity of the electrode placed over the targeted area (Woods *et al.*, 2016), whereby cortical excitability is increased beneath the anode and decreased beneath the cathode (Nitsche & Paulus, 2000). While TMS induces neuronal firing directly beneath the stimulation coil (Opitz *et al.*, 2011), tDCS is thought to enhance a more diffused neuronal plasticity underneath the large electrodes on the scalp, potentially reaching broader regions of interest (Datta *et al.*, 2009; Opitz *et al.*, 2013; DaSilva *et al.*, 2015; Santos *et al.*, 2016; Huang *et al.*, 2017). Electrode placement was ensured by a premeasured strap (Soterix Medical, Inc., New York, USA),

fitted to the participant's headsize, on which the electrodes were snapped. Every electrode placement was photographed prior to each stimulation in order to assess the reliability of the positioning in-between sessions. The tDCS devices were pre-programmed to deliver real- or sham-tDCS by a co-author who was not involved in data acquisition or analyses, and both the experimenters and the participants were not aware of the applied treatment. In the real-tDCS condition, each stimulation delivered 2mA for a duration of 20 minutes. Stimulations started with a 30-second ramp up, during which the device slowly increased the amount of energy delivered to reach 2mA. A ramp down to zero occurred during the last 30 seconds of the stimulation. In order to maintain effective subject blinding, the sham-tDCS condition also included the 30 seconds ramp up from zero to 2mA followed by an immediate ramp down back to zero where the device did not deliver any current. At the end of the 20-minute sham-tDCS session, the same ramp up and ramp down was reproduced once again to mimic the tingling sensation under the electrodes usually reported by subjects receiving active stimulation (Brunoni *et al.*, 2011). The actual length of the stimulation for all sessions was recorded on the tDCS device and all recordings were verified after the study in order to ensure that each participant received the intended set amount of stimulation. The blind was only removed after the completion of the entire study inclusive of data analyses.

Behavioral Assessment and Outcome Measures

Neuropsychological tests evaluated: 1) handedness [modified Edinburgh Handedness Inventory (Milenkovic & Dragovic, 2013)]; 2) color blindness [abbreviated version of the Ishihara color blindness test (Ishihara, 1917) with all subjects except for one of normal color vision]; 3) estimated premorbid verbal IQ [Wide Range Achievement Test (Wilkinson, 1993) – Reading scale]; 4) estimated premorbid non-verbal IQ [Wechsler Abbreviated Scale of Intelligence (Wechsler, 1999) – Matrix Reasoning Subtest]; 5) verbal fluency (semantic and drug) (Goldstein

9

et al., 2007, 2009; Lezak *et al.*, 2012); and 6) the Kirby Delay Discounting Task for temporal discounting/impulsivity (Kirby *et al.*, 1999).

The primary outcome measures, aimed at replicating previous findings (Batista *et al.*, 2015), included the: 1) a subscale of the Obsessive-Compulsive Cocaine Scale (Vorspan *et al.*, 2012) that includes 5 items (1, 2, 4, 5, and 13) known to be specificaly associated with cocaine cravings (De Wildt *et al.*, 2005); 2) 5-item Cocaine Craving Questionnaire (Tiffany *et al.*, 1993) to further measure subjective cocaine craving; 3) Hamilton Anxiety Rating Scale (Hamilton, 1959) for state anxiety; 4) Hamilton Depression Rating Scale (Hamilton, 1960) for state depression; and 5) an abbreviated version of the World Health Organization Quality of Life (Skevington *et al.*, 2004) for measures of quality of life on four different domains (physical health, psychological, social relationship, and environment).

Secondary outcome measures included the Epworth Sleepiness Scale (Johns, 1991) assessing the likelihood of falling asleep in various situations (ranging from "would never doze" to "high chance of dozing"), the Pittsburgh Sleep Quality Index (Buysse *et al.*, 1989) to assess sleep quality as well as daily interviews to assess sleep quantity (number of hours of sleep during the previous night). Included were also the Contemplation Ladder (Biener & Abrams, 1991) that evaluates participants' willingness to change their drug use (with a score of 0 being associated with: "*No thoughts about quitting. I cannot live without drugs*," a score of 4 being associated with: "*I sometimes think about changing the way that I use drugs, but I have not planned to change it yet*," a score of 8 being associated with: "*I still use drugs, but I will begin to change, like cutting back on the amount of drugs that I use,*" and a score of 10 being associated with: "*I have changed my drug use and will never go back to the way I used drugs before."),* the Positive and Negative Affect Schedule (Watson *et al.*, 1988) assessing the positive and negative dimensions of mood, and

10

the Sensitivity to Reinforcement of Addictive and other Primary Rewards questionnaire (STRAP-R) (Goldstein *et al.*, 2010) to assess the liking and wanting of drug and non-drug rewards.

Statistical Analyses

A first set of statistical analyses was conducted to investigate group differences at baseline on demographic variables and the IQ measures. Continuous variables were compared using Student's T-tests whereas chi-squared (χ^2) tests were used for categorical variables. A second set of analyses aimed at assessing pre- vs. post-tDCS effects using 2 (Group: sham vs. real-tDCS) × 2 (Time: pre- vs. post-tDCS) analysis of variance (ANOVA) with repeated measures for variables of interest that included select neuropsychological tests, clinical drug variables as well as the primary and secondary outcome variables. Daily measures of cocaine craving and sleep quantity were assessed with two 2 (Group: sham vs. real-tDCS) × 15 (Time: all study sessions) ANOVAs with repeated measures. The STRAP-R data were analysed following a previously published procedure (Goldstein *et al.*, 2010) with a 2 (Group: sham vs. real-tDCS) × 3 (Reward: food, sex, drug) × 3 (Situation: 'current', 'in general', 'under the influence'), × 2 (Question: 'liking' and 'wanting'), × 2 (Times: pre-tDCS, post-tDCS) mixed repeated-measures ANOVA. Finally, in order to investigate any potential longer-lasting effects of tDCS stimulation, additional 2 (Group: sham vs. real-tDCS) × 3 (Time: pre-tDCS, post-tDCS, and 1-month follow-up) ANOVAs with repeated measures were carried out for the primary and secondary variables that showed any significant Time or Group × Time interactions in the first set of ANOVAs. In all ANOVAs, simple effects were analyzed to follow-up significant interactions. Greenhouse-Geisser correction was used for repeated measures ANOVAs if needed. Covariates were the demographic, neuropsychological or clinical drug use measures that differed between the groups and correlated with any of the outcome measures that showed any significant results (Pocock *et al.*, 2002). For this pilot small N study,

11

corrections for multiple comparisons were not undertaken and results were considered significant at p < 0.05 for all outcome measures. Results with p < 0.1 are reported as showing a trend.

Results

Demographic Variables and Neuropsychological Tests

Supporting the randomization procedure and the creation of matched groups, there were no significant group differences at baseline in any of the demographic variables or neuropsychological tests (Table 1, which includes Cohen's d effect sizes for the repeated measures ANOVA). A main effect for Time was significant for the Kirby Delay Discounting Task, where both groups showed decreased values of k from pre- to post-tDCS suggesting improvement in the ability to value delayed rewards with inpatient treatment [$F(1,12) = 5.68$, $p = 0.035$, $d = 1.4$]. There were no other Time or interaction effects that reached significance for the neuropsychological tests [$F(1,12) < 1.64$, $p > 0.225$, $d < .74$].

Clinical Drug Use Measures

Our 2×2 ANOVAs with repeated measures showed the expected significant increase in abstinence length (days) in both groups [$F(1,12) = 31.5$, $p = 0.01$, $d = 3.2$] from pre- to post-tDCS, suggesting adherence to the inpatient treatment. A significant group effect was detected for the Cocaine Negative Consequences Checklist where the real-tDCS group reported overall less negative consequences of cocaine use than the sham-tDCS group [$F(1,12) = 6.53$, $p = 0.025$, $d = 1.5$]; since this measure did not correlate with any of the outcome measures that showed significant results (below), we did not include it as a covariate in the subsequent analyses. There were no other significant effects for any of the other drug use variables including lifetime cocaine use, severity of dependence, and withdrawal symptoms at time of study.

12

Primary Outcome Measures

The 2 (Group) × 2 (Time) ANOVA with repeated measures with the 5-item Obsessive-Compulsive Cocaine Scale craving subscale yielded no significant effects. However, since a trend for a Group effect (p = 0.1, one-tailed statistical test) was observed, we explored the same ANOVA with repeated measures while correcting for baseline values. This analysis showed a trend for a significant Group × Time interaction [$F_{(1,11)}$ = 3.885, p = 0.074, Figure 2A] where only the real-tDCS group showed decreased self-reported craving scores after 15 sessions of stimulation. Power analysis (G*Power v3.1.9.4) suggested that 15 subjects per group would allow sufficient power (80%) for detecting this effect at the .05 significance level. The ANOVA for the 5-item Cocaine Craving Questionnaire showed a trend for a Time effect [$F_{(1,12)}$ = 4.17, p = 0.064, *d* = 1.2, Figure 2B] that was further supported by a closer look at the self-reported craving intensity item on the Cocaine Selective Severity Assessment, showing a significant Time effect [$F_{(1,12)}$ = 7.15, p = 0.020, *d* = 1.5, Figure 2C], together suggesting decreased self-reported craving from pre- to post-tDCS. Similarly, the 2 × 15 ANOVA for the daily self-report of cocaine craving revealed a trend for a Time main effect [$F_{(14,168)}$ = 1.63, p = 0.075, d = .20, Figure 4A], with a linear contrast reaching significance (p < 0.05) to suggest a linear decrease in craving over the 15 sessions across all subjects. A Time main effect was also significant for the World Health Organization Quality of Life, the environment scale [$F_{(1,12)}$ = 10.92, p = 0.006, *d* = 1.9], which increased from pre- to post-tDCS in both groups, again consistent with adherence to the inpatient treatment and the overall longer abstinence. No significant effects were observed for state depression or anxiety [$F_{(1,12)}$ < 1.87, p > 0.197, d < .79].

Secondary Outcome Measures

The 2 × 2 ANOVAs with repeated measures showed a significant Group × Time interaction for the Epworth Sleepiness Scale [$F_{(1,11)}$ = 5.18, p = 0.044, *d* = 1.4, Figure 3A]; the main effects

13

of Group and Time were not significant [$F(1,11) < 3.05$, $p > 0.109$, $d < 1.1$]. Follow-up analyses showed that this interaction was explained by a group difference (real-tDCS < sham-tDCS) post [$t(12) = 2.48$, $p = 0.029$] but not pre-tDCS [$t(11) = 0.30$, $p = 0.774$)] suggesting that individuals with CUD who received real-tDCS reported less sleepiness than those in the sham-tDCS group after all 15 tDCS sessions. The 2 × 15 ANOVA of the daily reports of the amount of sleep yielded corroborating results (Figure 4B). Here, the Group by Time interaction did not reach significance [$F(14,168) = 0.74$, $p = 0.729$, $d = .13$], instead revealing a Group main effect (real-tDCS > sham-tDCS) [$F(1,12) = 7.15$, $p = 0.020$, $d = 1.5$]. Subsequent exploratory t-tests however showed real- as compared to the sham-tDCS participants to report significantly more hours of sleep after the 5th [$t(12) = -2.43$, $p = 0.032$], 9th [$t(12) = -3.08$, $p = 0.009$], 11th [$t(12) = -2.31$, $p = 0.040$], and 12th [$t(12) = -2.58$, $p = 0.024$] sessions with similar trends for the 8th [$t(12) = -2.41$, $p = 0.054$] and 15th [$t(12) = -2.03$, $p = 0.065$] sessions but not for the first 4 sessions [$t(12) < -1.52$, $p > 0.155$], indicating that the groups started differentiating later during treatment (See Figure 4B). In contrast, sleep quality, as measured by the Pittsburgh Sleep Quality Index, showed a Time main effect, indicative of a decrease in the overall sleep quality during inpatient treatment in both groups [$F(1,11) = 5.02$, $p = 0.047$, $d = 1.4$]. A Group × Time interaction [$F(1,12) = 5.40$, $p = 0.039$, $d = 1.3$, Figure 3B] was also significant for the Contemplation Ladder where simple effects showed a trend towards increase in readiness to change in the real-tDCS [$t(7) = -2.35$, $p = 0.051$] but not sham-tDCS [$t(5) = 1.0$, $p = 0.363$] group (Figure 3B), suggesting higher readiness to change after the stimulation sessions in the real-tDCS group.

One-Month Follow-Up

Using 2 (Group) × 3 (Time) ANOVAs with repeated measures, analyses were carried out for the three outcome variables that showed significant Group × Time interactions (or a trend) and for all outcome variables (in addition to the craving intensity item on the Cocaine Selective Severity

14

Assessment) that showed a significant Time effect (Table 1, Figure 5). While correcting for baseline value, no Group × Time interaction was found for the 5-item OCCS craving subscale [$F(2,18) = 2.32$, $p = 0.127$, Figure 5A] but a significant Group effect is otherwise found where the real-tDCS group shows lower craving scores than the sham-tDCS group [$F(1,9) = 6.31$, $p < 0.033$]. Although no significant effect was found for the 5-item Cocaine Craving Questionnaire [$F(2,20) < 2.11$, $p > 0.147$, Figure 5B] either, the craving question of the Cocaine Selective Severity Assessment showed a significant Time effect, driven by decreases in cocaine cravings during treatment and their increase back to baseline one month following the protocol [$F(2,20) = 3.62$, $p = 0.045$]. A significant interaction effect for the Epworth Sleepiness Scale [$F(2,9) = 6.07$, $p = 0.011$, Table 2 and Figure 5C] was driven by a significant time effect only in the real-tDCS group [$F(1,6) = 5.71$, $p = 0.021$] such that participants reported more sleepiness at follow-up when compared to the immediate post-tDCS assessment ($p = 0.009$) suggesting that values returned to baseline after one month follow-up in this group. There were no significant effects for the Contemplation Ladder [$F(2,20) < 1.75$, $p > 0.199$, Figure 5D] nor for the Pittsburgh Sleep Quality Index [$F(2,18) < 2.20$, $p > 0.172$, Figure 5F]. The environment domain of the Quality of Life Questionnaire showed a significant Time effect [$F(2,20) = 5.70$, $p = 0.011$, Figure 5E] where values were higher in both groups after the 15 tDCS sessions, remaining elevated after a one-month follow-up ($p < 0.05$).

STRAP-R

Our 5-way mixed ANOVA showed main effects of Group [sham-tDCS > real-tDCS, $F(1,12) = 9.48$, $p = 0.010$], Reward [Food = Sex > Drug, $F(2,24) = 16.35$, $p < 0.0001$], and Question ["liking" > "wanting", $F(1,12) = 9.24$, $p = 0.010$), and Situation × Question [$F(2,24) = 10.22$, $p = 0.001$] and Reward × Situation [$F(4,48) = 16.57$, $p < 0.0001$] interactions quantified by a significant 3-way Reward × Situation × Question interaction [$F(4,48) = 4.04$, $p = 0.007$] (See Table 3). To

15

follow up on the significant interactions, 3 (Situation) × 2 (Question) ANOVAs with repeated measures were carried out independently for each Reward type. For the Food reward, there were significant Situation ["now" = "in general" > "under the influence", $F(1.27,16.45) = 6.54$, $p < 0.016$] and Question effects ["liking" > "wanting", $F(1,13) = 5.17$, $p = 0.041$] . The Sex reward showed the same Question effect ["liking" > "wanting", $F(1,13) = 5.56$, $p = 0.035$]; there were no other significant effects [$F < 1.40$, $p > 0.269$]. Consistent with our prior reports (Goldstein *et al.*, 2010), for the Drug reward, there was a significant Situation main effect ["now" < "in general" < "under the influence", $F(2,26) = 33.56$, $p < 0.0001$]. A significant Situation × Question interaction effect was also observed [$F(1.39, 18.03) = 13.02$, $p = 0.001$] and showed that "liking" was higher than "wanting" for both the "now" ($t(13) = 3.37$, $p = 0.005$) and "in general" ($t(13) = 2.68$, $p = 0.019$) situations whereas "wanting" was higher than "liking" for the "under the influence" ($t(13) = -3.30$, $p = 0.006$) situation. No significant effects for Time [$F(1,12) = 0.44$, $p = 0.522$] or interactions with Time or Group [$F < 2.18$, $p > 0.135$] were however found for the STRAP-R questionnaire.

Discussion

The main goal of this Phase 1 clinical trial was to replicate previous findings showing a reduction in subjective cocaine cravings associated with repeated tDCS over the dlPFC in individuals with CUD living in an inpatient drug-rehabilitation facility (Batista *et al.*, 2015). Using a portable device in such a non-medical setting, our study also aimed at assessing the feasibility of an extended protocol of 15 repeated sessions of tDCS. Feasibility was clearly evident in the completion of all 15 sessions in 14 of the 17 subjects who started this study (82% retention rate); future studies need to take into account drop-outs driven by subjects' transfer to different treatment

16

facilities that may not allow participation in research-related activities. Beyond treatment-as-usual effects evident in longer abstinence duration, enhanced perceived quality of the environment and sleep measures, and in reduced impulsivity, our main finding provided partial support for the impact of real-tDCS on reducing craving. Importantly, we observed decreased self-reported daytime sleepiness and increased readiness to change in the real-tDCS group only. The real-tDCS effect on sleepiness was not maintained after a one-month follow-up, a result that needs to be tested with larger samples.

Previous findings showed a significant decrease in subjective cocaine craving specifically in the real-tDCs group (Batista *et al.*, 2015), bolstered by similar results in individuals using other psychostimulants such as methamphetamine and nicotine (Fecteau *et al.*, 2014; Shahbabaie *et al.*, 2014, 2018; Hajloo *et al.*, 2019; Martinotti *et al.*, 2019; Alizadehgoradel *et al.*, 2020). Our results provide partial support for our main hypothesis for a similar unique effect of real-tDCS on craving in our subjects. Using the 5-item Obsessive-Compulsive Cocaine Scale craving subscale (De Wildt *et al.*, 2005), the tool used by the previous study, a Group by Time interaction showed a trend toward significance when correcting for baseline values and using a one-tailed threshold. For this effect to reach significance, 30 individuals with CUD (15 in each group) would need to be enrolled in a Phase 2 study. Our other craving measures mainly showed a Time main effect such that participants in both groups reported less cravings after vs. before the experiment. This Time effect was observed for the self-reported craving intensity item on the Cocaine Selective Severity Assessment (Kampman *et al.*, 1998) supported by a significant linear decrease over time in the 15 daily self-reports of cocaine craving with a similar trend also for the 5-item Cocaine Craving Questionnaire (Tiffany *et al.*, 1993). Overall, this decrease in craving for both the study groups can be attributed to drawing our sample from treatment-seeking individuals living in an inpatient facility, a controlled and structured therapeutic environment. Batista and colleagues (2015) also

17

reported that only the real-tDCS (and not sham) treatment was associated with a decrease in anxiety and depressive symptoms and higher levels in self-reported quality of life (in the psychological and environment domains). Consistent with the treatment environment, we observed a significant increase in the perception of the quality of the environment in both the real- and sham-tDCS groups, while effects for anxiety and depression were not significant, potentially because of insufficient statistical power and the need for larger sample sizes. Our results also showed a significant decrease in impulsivity with time in inpatient treatment, with both groups better able to value monetary reinforcement even if delayed in time (Odum, 2011; Mejía-Cruz *et al.*, 2016). The association between impulsivity and craving deserves further exploration especially in light of a recent study in patients with alcohol use disorder showing that increased impulsivity was associated with higher craving, which, in turn, increased the likelihood of alcohol use in treatment, suggesting that craving mediates the relationship between impulsivity and the likelihood to relapse (Coates *et al.*, 2020).

Our exploratory results showed a specific decrease in self-reported daytime sleepiness, suggesting an increase in alertness that is characteristic of initial abstinence (Conroy & Arnedt, 2014), only in the real-tDCS (and not sham) group. Although the Group by Time interaction did not reach significance in this small sample, the daily measures of sleep quantity showed similar effects such that the real-tDCS group reported sleeping on average more hours than the sham-tDCS group, an effect reaching significance in later sessions only (starting at the fifth session), suggesting a cumulative effect of real-tDCS on sleep quantity. The seemingly contradictory significant Time effect on the Pittsburgh Sleep Quality Index, where both groups reported a decrease in sleep quality after all tDCS sessions, could reflect the inpatient conditions where subjects share bedrooms similar to dormitories with no possibility for individual adjustments (e.g., in sleep/wake cycle). Overall, our results are consistent with other tDCS studies targeting the dlPFC with different electrode setups (left dlPFC anodal electrode and single or multiple cathodal electrodes throughout the scalp)

18

where real-tDCS increased the total sleep duration in normal adults (Frase *et al.*, 2016) and older healthy adults (Sheng *et al.*, 2018); our results are not consistent with studies reporting increases in sleep-quality, e.g., in euthymic bipolar patients (Minichino *et al.*, 2014). The exact mechanisms underlying the putative effect of tDCS on sleep are yet to be fully investigated but of note is an alteration of resting-state functional MRI connectivity between the default mode network and subcortical regions, including the amygdala, hippocampus, striatum, globus pallidus, and thalamus, after high-definition tDCS in older adults (Sheng *et al.*, 2018), known for their crucial role in sleep-wake functions (Pace-Schott & Hobson, 2002; Sämann *et al.*, 2011; De Havas *et al.*, 2012).

In addition, participants in the real-tDCS but not sham-tDCS group reported a higher motivation to change as measured by the Contemplation Ladder after (vs. before) all 15 sessions. Motivation to change is an inherent part of drug rehabilitation, associated with engagement in recovery-oriented behaviors (Gregoire & Burke, 2004) and predictive of changes in drug consumption (Heather *et al.*, 1993). During a recent functional MRI reappraisal task performed by cocaine addicted individual, readiness to change was positively correlated with the right dlPFC response to emotional regulation and negatively with its response to emotional processing, prompting the authors to propose that a greater top-down control of negative emotionality and reactivity is associated with maintaining goal-oriented behaviors (Contreras-Rodríguez *et al.*, 2020). It is therefore possible that our tDCS protocol that targeted the right dlPFC enhanced subjects' motivation to change through a top-down executive control mechanism, potentially contributing to both the persistence towards reducing drug use and the ability to flexibly learn alternatives to current strategies for maintaining abstinence, consistent with the iRISA model (Volkow *et al.*, 2010; Goldstein & Volkow, 2011; Hobkirk *et al.*, 2019) as remains to be studied with objective measures.

19

This iRISA syndrome is associated with enhanced attribution of salience to drug-related cues and with decreased sensitivity to non-drug reinforcers; we therefore evaluated the effects of tDCS on self-reported sensitivity to reinforcement of addictive and other primary rewards using the STRAP-R questionnaire. Although we did not observe significant Time or Group interactions, suggesting this sensitivity may mostly reflect trait measures not affected by tDCS, we corroborated previous results where the subjective value of drug and non-drug reinforcers depended on the situation (Goldstein *et al.*, 2010). More precisely, individuals with CUD gave a higher "liking" than "wanting" ratings in all situations ("current", "in general" and "under the influence") for non-drug reinforcers (food and sex) whereas they exhibited more drug "wanting" than "liking" when reporting about being "under the influence". These results support the idea that drug stimuli are wanted (potentially underlying habit and compulsion) more than they are liked (hedonic properties) especially during a drug-cue context in addiction (Goldstein & Volkow, 2002, 2011; Goldstein *et al.*, 2010).

A major limitation of this study is its small sample size (especially during the follow-up assessment), potentially reducing statistical power by increased interindividual variability characterizing the effects of non-invasive brain stimulation on cortical plasticity (Ridding & Ziemann, 2010; López-Alonso *et al.*, 2014). Another limitation is the use of self-report to assess craving, which could reflect habituation and/or floor or other effects (e.g., compromised self-awareness). A Phase 2 clinical trial should include more participants in each group as well as objective measures of cocaine craving such as drug-related cue-reactivity (e.g., assessed by electroencephalography and event-related potentials), which may be more sensitive to our effects of interest. Indeed, these objective measures tracked cue-induced incubation of craving, showing a discrepancy with subjective measures of cocaine craving during abstinence in individuals with CUD (Parvaz *et al.*, 2016). Our study suggests only a transient effect of tDCS on sleepiness and

20

craving when tested about one month after the last tDCS session. Further studies are needed to establish the tDCS dose and duration needed for optimally maintaining any beneficial impact in inpatients with CUD. Finally, the impact of medications (taken by all our participants) on results remains to be systematically studied. Some studies suggest that pharmacotherapy in combination with electrical brain stimulation yield greater effects (than brain stimulation or pharmacotherapy alone) in depression (Brunoni *et al.*, 2013, 2014), although other studies suggest no significant effects of pharmacotherapy on decreasing craving, observed in both the experimental and control groups after 10 sessions of repeated tDCS in inpatients with CUD (Klauss *et al.*, 2018).

To summarize, our study in individuals with CUD showed a trend towards a unique effect of real-tDCS on craving, an effect that could reach significance with 15 subjects per group. In this small sample, inpatient treatment itself, and the ensuing longer abstinence, was associated with a reduction in self-reported craving and improvements in the perceived quality of the environment as well as with reduced impulsivity/improvements in valuation of delayed rewards (but not with changes in the value attributed to drug-related rewards especially when thinking about a drug-relevant context). Interestingly, real-tDCS (but not sham-tDCS) was associated with reductions in daytime sleepiness and increases in readiness to change potentially suggesting the fortification of executive cognitive functions supported by the dlPFC. A main result from this Phase 1 project was also the demonstration of the feasibility of using a portable tDCS device 15 times over 5 weeks in inpatients with CUD. Overall, our results suggest the need for extending this proof-of-concept study to establish the use of tDCS as an add-on therapy in drug addiction. Specifically, these results call for a larger sample further incorporating objective (e.g., psychophysiological) outcome measures and ultimately assessing the remote and self-administration of tDCS (e.g., in other in- and out-patient drug rehabilitation facilities, in combination with other cognitive and

pharmacological therapies, and ultimately at home) for the purpose of managing drug addiction symptomatology.

Figure Legends

Figure 1: Representation of Phase 1 clinical trial protocol and recruitment, randomization and assessment of participants.

Figure 2: Group-averaged total scores for cocaine craving at both timepoints (pre- and post-tDCS).

A) Left panel: group-averaged baseline-corrected total score on the 5-item Obsessive-Compulsive Cocaine Scale craving subscale at both study timepoints (pre- and post-tDCS). Given the trend for a Group effect (p = 0.1, one-tailed statistical test), we explored the 2 × 2 ANOVA with repeated measures while correcting for baseline values. This analysis showed a trend for a significant Group × Time interaction ([†] p = 0.074) where only the real-tDCS group showed decreased self-reported craving scores after 15 sessions of stimulation. Power analysis suggested that 15 subjects per group would allow sufficient power for detecting this effect at the .05 significance level. Middle panel: Individual scores showing change from pre- to post-tDCS in each group. Right panel: All subjects scores at both study timepoints.

B) Left panel: group-averaged total score on the 5-item Cocaine Craving Questionnaire at both study timepoints (pre- and post-tDCS). Results showed a trend for a Time effect ([†] p = 0.064). Middle panel: Individual scores showing change from pre- to post-tDCS in each group. Right panel: All subjects scores at both study timepoints showing the trend for a Time effect.

22

C) Left panel: group-averaged total score on the craving intensity item of the Cocaine Selective Severity Assessment at both study timepoints (pre- and post-tDCS). Results showed a significant Time effect (* $p < 0.05$). Middle panel: Individual scores showing change from pre- to post-tDCS in each group. Right panel: All subjects scores at both study timepoints showing the significant Time effect.

Figure 3: Significant Group × Time interactions for sleepiness and motivation to change.

A) Left panel: group-averaged total score on the Epworth Sleepiness Scale at both study timepoints (pre- and post-tDCS). The significant Group × Time interaction was driven by a group difference post-tDCS (* $p < 0.05$). Right panel: Individual scores showing change from pre- to post-tDCS in each group.

B) Left panel: group-averaged total score on the Contemplation Ladder at both study timepoints (pre- and post-tDCS). The significant Group × Time interaction was driven by a trend for an increase in readiness to change in the real-tDCS group only ([†] $p = 0.05$). Right panel: Individual scores showing change from pre- to post-tDCS in each group.

Figure 4: Group-averaged number of hours of daily sleep and daily self-reported cocaine craving for all stimulation sessions.

A) A trend for a Time main effect ($p = 0.075$) was found for the daily self-reported cocaine craving on a scale of 0 to 7. A linear contrast reached significance ($p < 0.05$) suggesting a linear decrease in craving over the 15 sessions across all subjects.

B). A Group main effect (Real- > Sham-tDCS; $p < 0.05$) was driven by significantly more sleeping hours after the 5th, 9th, 11th, and 12th sessions with similar trends for the 8th and 15th sessions. [†] $p = 0.05$; * $p < 0.05$.

23

Figure 5: <u>One-month follow-up of craving, daytime sleepiness, readiness to change, sleep quality, and quality of life.</u>

Group-averaged total scores on all measures that showed significant Group × Time interactions and for all outcome variables that showed a significant Time effect (or a trend) for all three study timepoints (pre-tDCS, post-tDCS, and follow-up). Those measures were the 5-item OCCS craving subscale (A), 5-item Cocaine Cravings Questionnaire (B), Epworth Sleepiness Scale (C), Contemplation Ladder (D), the Environment domain of the abbreviated version of the World Health Organization Quality of Life questionnaire (E), and the Pittsburgh Sleep Quality Index (F). A Group × Time interaction on the Epworth Sleepiness Scale was driven by a time effect only in the real-tDCS group such that participants reported more sleepiness at follow-up when compared to the immediate post-tDCS assessment (** $p < 0.01$). A significant Group effect was found for the 5-item OCCS craving subscale when correcting for baseline values where the real-tDCS group showed lower cravings than the sham-tDCS group ($p < 0.05$). A significant Time effect was also found for the Environment domain of the Quality of Life questionnaire ($p < 0.05$).

Acknowledgements

Competing Interests

Parra and Datta hold shares in Soterix Medical Inc. They were involved in the design of this trial, but not in the execution of the trial, nor in the data analysis, or interpretation of the results.

Author Contributions

Study design: Datta, Parvaz, Parra, Alia-Klein, Goldstein and Nakamura-Palacios (consultant).

Intervention blinding: Parvaz and Goldstein. Study implementation: Gaudreault, Datta, Malaker, and Wagner. Data acquisition: Gaudreault, Sharma, King, Malaker, Wagner and Vasa. Data analysis: Gaudreault and Sharma. Manuscript writing: Gaudreault, Sharma and Goldstein. Manuscript review: Datta, Nakamura-Palacios, Parvaz, Parra, Alia-Klein and Goldstein.

Data Accessibility

Data acquired for this project are available upon request to Dr. Rita Z. Goldstein.

References

Alizadehgoradel, J., Nejati, V., Sadeghi Movahed, F., Imani, S., Taherifard, M., Mosayebi-Samani, M., Vicario, C.M., Nitsche, M.A., & Salehinejad, M.A. (2020) Repeated stimulation of the dorsolateral-prefrontal cortex improves executive dysfunctions and craving in drug addiction: A randomized, double-blind, parallel-group study. *Brain Stimul.*, **13**, 582–593.

Batista, E.K., Klauss, J., Fregni, F., Nitsche, M.A., & Nakamura-Palacios, E.M. (2015) A randomized placebo-controlled trial of targeted prefrontal cortex modulation with bilateral tDCS in patients with crack-cocaine dependence. *Int. J. Neuropsychopharmacol.*, **18**, 1–11.

Biener, L. & Abrams, D.B. (1991) The Contemplation Ladder: Validation of a Measure of Readiness to Consider Smoking Cessation. *Heal. Psychol.*, **10**, 360–365.

Bindman, L.J., Lippold, O.C.J., & Redfearn, J.W.T. (1964) The action of brief polarizing currents

on the cerebral cortex of the rat (1) during current flow and (2) in the production of long-

lasting after-effects. *J. Physiol.*, **172**, 369–382.

Bolloni, C., Panella, R., Pedetti, M., Frascella, A.G., Gambelunghe, C., Piccoli, T., Maniaci, G.,

Brancato, A., Cannizzaro, C., & Diana, M. (2016) Bilateral transcranial magnetic

stimulation of the prefrontal cortex reduces cocaine intake: A pilot study. *Front. Psychiatry*,

7, 1–6.

Brunoni, A.R., Amadera, J., Berbel, B., Volz, M.S., Rizzerio, B.G., & Fregni, F. (2011) A

systematic review on reporting and assessment of adverse effects associated with

transcranial direct current stimulation. *Int. J. Neuropsychopharmacol.*, **14**, 1133–1145.

Brunoni, A.R., Júnior, R.F., Kemp, A.H., Lotufo, P.A., Benseñor, I.M., & Fregni, F. (2014)

Differential improvement in depressive symptoms for tDCS alone and combined with

pharmacotherapy: An exploratory analysis from the Sertraline Vs. Electrical Current

Therapy for Treating Depression Clinical Study. *Int. J. Neuropsychopharmacol.*, **17**, 53–61.

Brunoni, A.R., Valiengo, L., Baccaro, A., Zanão, T.A., De Oliveira, J.F., Goulart, A., Boggio,

P.S., Lotufo, P.A., Benseñor, I.M., & Fregni, F. (2013) The sertraline vs electrical current

therapy for treating depression clinical study. *JAMA Psychiatry*, **70**, 383–391.

Buysse, D.J., Reynolds, C.F., Monk, T.H., Berman, S.R., & Kupfer, D.J. (1989) The Pittsburgh

Sleep Quality Index - a new instrument for assessing sleep in psychiatric practice and

research. *Psychiatry Res.*, **28**, 193–213.

Camprodon, J.A., Martínez-Raga, J., Alonso-Alonso, M., Shih, M.C., & Pascual-Leone, A.

(2007) One session of high frequency repetitive transcranial magnetic stimulation (rTMS) to

the right prefrontal cortex transiently reduces cocaine craving. *Drug Alcohol Depend.*, **86**,

91–94.

Charest, J., Marois, A., & Bastien, C.H. (2019) Can a tDCS treatment enhance subjective and

objective sleep among student-athletes? *J. Am. Coll. Heal.*, **0**, 1–12.

Chaves, T. V., Sanchez, Z.M., Ribeiro, L.A., & Nappo, S.A. (2011) Crack cocaine craving: Behaviors and coping strategies among current and former users. *Rev. Saude Publica*, **45**, 1168–1175.

Coates, J.M., Gullo, M.J., Feeney, G.F.X., McD. Young, R., Dingle, G.A., Clark, P.J., & Connor, J.P. (2020) Craving mediates the effect of impulsivity on lapse-risk during alcohol use disorder treatment. *Addict. Behav.*, **105**, 106286.

Conroy, D.A. & Arnedt, J.T. (2014) Sleep and substance use disorders: an update. *Curr Psychiatry Rep*, **16**, 487.

Conti, C.L., Moscon, J.A., Fregni, F., Nitsche, M.A., & Nakamura-Palacios, E.M. (2014) Cognitive related electrophysiological changes induced by non-invasive cortical electrical stimulation in crack-cocaine addiction. *Int. J. Neuropsychopharmacol.*, **17**, 1465–1475.

Conti, C.L. & Nakamura-Palacios, E.M. (2014) Bilateral transcranial direct current stimulation over dorsolateral prefrontal cortex changes the drug-cued reactivity in the anterior cingulate cortex of Crack-cocaine addicts. *Brain Stimul.*, **7**, 130–132.

Contreras-Rodríguez, O., Albein-Urios, N., Miguel Martinez-Gonzalez, J., Menchón, J.M., Soriano-Mas, C., & Verdejo-García, A. (2020) The neural interface between negative emotion regulation and motivation for change in cocaine dependent individuals under treatment.

DaSilva, A.F., Truong, D.Q., DosSantos, M.F., Toback, R.L., Datta, A., & Bikson, M. (2015) State-of-art neuroanatomical target analysis of high-definition and conventional tDCS montages used for migraine and pain control. *Front. Neuroanat.*, **9**, 1–12.

Datta, A., Bansal, V., Diaz, J., Patel, J., Reato, D., & Bikson, M. (2009) Gyri-precise head model of transcranial direct current stimulation : Improved spatial focality using a ring electrode

27

versus conventional rectangular pad. *Brain Stimul.*, **2**, 201-207.e1.

De Almeida Ramos, R., Taiar, I., Trevizol, A.P., Shiozawa, P., & Cordeiro, Q. (2016) Effect of a ten-day prefrontal transcranial direct current stimulation protocol for crack craving a proof-of-concept trial. *J. ECT*, **32**, e8–e9.

De Havas, J.A., Parimal, S., Soon, C.S., & Chee, M.W.L. (2012) Sleep deprivation reduces default mode network connectivity and anti-correlation during rest and task performance. *Neuroimage*, **59**, 1745–1751.

De Wildt, W.A.J.M., Lehert, P., Schippers, G.M., Nakovics, H., Mann, K., & Van Den Brink, W. (2005) Investigating the structure of craving using structural equation modeling in analysis of the obsessive-compulsive drinking scale: A multinational study. *Alcohol. Clin. Exp. Res.*, **29**, 509–516.

Ekhtiari, H., Tavakoli, H., Addolorato, G., Baeken, C., Bonci, A., Campanella, S., Castelo-Branco, L., Challet-Bouju, G., Clark, V.P., Claus, E., Dannon, P.N., Del Felice, A., den Uyl, T., Diana, M., di Giannantonio, M., Fedota, J.R., Fitzgerald, P., Gallimberti, L., Grall-Bronnec, M., Herremans, S.C., Herrmann, M.J., Jamil, A., Khedr, E., Kouimtsidis, C., Kozak, K., Krupitsky, E., Lamm, C., Lechner, W. V., Madeo, G., Malmir, N., Martinotti, G., McDonald, W.M., Montemitro, C., Nakamura-Palacios, E.M., Nasehi, M., Noël, X., Nosratabadi, M., Paulus, M., Pettorruso, M., Pradhan, B., Praharaj, S.K., Rafferty, H., Sahlem, G., Salmeron, B. jo, Sauvaget, A., Schluter, R.S., Sergiou, C., Shahbabaie, A., Sheffer, C., Spagnolo, P.A., Steele, V.R., Yuan, T. fei, van Dongen, J.D.M., Van Waes, V., Venkatasubramanian, G., Verdejo-García, A., Verveer, I., Welsh, J.W., Wesley, M.J., Witkiewitz, K., Yavari, F., Zarrindast, M.R., Zawertailo, L., Zhang, X., Cha, Y.H., George, T.P., Frohlich, F., Goudriaan, A.E., Fecteau, S., Daughters, S.B., Stein, E.A., Fregni, F., Nitsche, M.A., Zangen, A., Bikson, M., & Hanlon, C.A. (2019) Transcranial electrical and

magnetic stimulation (tES and TMS) for addiction medicine: A consensus paper on the

present state of the science and the road ahead. *Neurosci. Biobehav. Rev.*, **104**, 118–140.

Fecteau, S., Agosta, S., Hone-Blanchet, A., Fregni, F., Boggio, P., Ciraulo, D., & Pascual-Leone,

A. (2014) Modulation of smoking and decision-making behaviors with transcranial direct

current stimulation in tobacco smokers: A preliminary study. *Drug Alcohol Depend.*, **140**,

78–84.

First, M.B. (2015) Structured Clinical Interview for the DSM (SCID) . *Encycl. Clin. Psychol.*, 1–

6.

Foltin, R.W. (1999) Food and Cocaine Self-Administration By Baboons: Effects of Alternatives.

J. Exp. Anal. Behav., **72**, 215–234.

Fonteneau, C., Redoute, J., Haesebaert, F., Le Bars, D., Costes, N., Suaud-Chagny, M.F., &

Brunelin, J. (2018) Frontal transcranial direct current stimulation induces dopamine release

in the ventral striatum in human. *Cereb. Cortex*, **28**, 2636–2646.

Frase, L., Piosczyk, H., Zittel, S., Jahn, F., Selhausen, P., Krone, L., Feige, B., Mainberger, F.,

Maier, J.G., Kuhn, M., Klöppel, S., Normann, C., Sterr, A., Spiegelhalder, K., Riemann, D.,

Nitsche, M.A., & Nissen, C. (2016) Modulation of Total Sleep Time by Transcranial Direct

Current Stimulation (tDCS). *Neuropsychopharmacology*, **41**, 2577–2586.

Garavan, H., Kaufman, J.N., & Hester, R. (2008) Acute effects of cocaine on the neurobiology of

cognitive control. *Philos. Trans. R. Soc. B Biol. Sci.*, **363**, 3267–3276.

Goldstein, R.Z., Tomasi, D., Alia-Klein, N., Carrillo, J.H., Maloney, T., Woicik, P.A., Wang, R.,

Telang, F., & Volkow, N.D. (2009) Dopaminergic response to drug words in cocaine

addiction. *J. Neurosci.*, **29**, 6001–6006.

Goldstein, R.Z. & Volkow, N.D. (2002) Drud addiction and its underlying neurobiological basis:

neuroimaging evidence for the involvment of the frontal cortex. *Am J Psychiatry*, **159**,

1642–1652.

Goldstein, R.Z. & Volkow, N.D. (2011) Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. *Nat. Rev. Neurosci.*, **12**, 652–669.

Goldstein, R.Z., Woicik, P.A., Lukasik, T., Maloney, T., & Volkow, N.D. (2007) Drug fluency: A potential marker for cocaine use disorders. *Drug Alcohol Depend.*, **89**, 97–101.

Goldstein, R.Z., Woicik, P.A., Moeller, S.J., Telang, F., Jayne, M., Wong, C., Wang, G.J., Fowler, J.S., & Volkow, N.D. (2010) Liking and wanting of drug and non-drug rewards in active cocaine users: The STRAP-R questionnaire. *J. Psychopharmacol.*, **24**, 257–266.

Gorini, A., Lucchiari, C., Russell-Edu, W., & Pravettoni, G. (2014) Modulation of risky choices in recently abstinent dependent cocaine users: A transcranial direct-current stimulation study. *Front. Hum. Neurosci.*, **8**, 1–9.

Gregoire, T.K. & Burke, A.C. (2004) The relationship of legal coercion to readiness to change among adults with alcohol and other drug problems. *J. Subst. Abuse Treat.*, **26**, 35–41.

Hajloo, N., Pouresmali, A., Goradel, J.A., & Mowlaie, M. (2019) The effects of transcranial direct current stimulation of dorsolateral prefrontal cortex on reduction of craving in daily and social smokers. *Iran. J. Psychiatry*, **14**, 291–296.

Hallett, M. (2007) Transcranial Magnetic Stimulation: A Primer. *Neuron*, **55**, 187–199.

Hamilton, M. (1959) The Assessment of Anxiety States By Rating. *Br. J. Med. Psychol.*, **32**, 50–55.

Hamilton, M. (1960) A Rating scale for depression. *J. Neurol. Neurosurg. Psychiatry*, **23**, 56–62.

HEATHER, N., ROLLNICK, S., & BELL, A. (1993) Predictive validity of the Readiness to Change Questionnaire. *Addiction*, **88**, 1667–1677.

Hennessy, G., De Menil, V., & Weiss, R.D. (2003) Psychosocial treatments for cocaine dependence. *Curr. Psychiatry Rep.*, **5**, 362–364.

Hobkirk, A.L., Bell, R.P., Utevsky, A. V., Huettel, S., & Meade, C.S. (2019) Reward and
executive control network resting-state functional connectivity is associated with
impulsivity during reward-based decision making for cocaine users. *Drug Alcohol Depend.*,
194, 32–39.

Huang, Y., Liu, A.A., Lafon, B., Friedman, D., Dayan, M., Wang, X., Bikson, M., Doyle, W.K.,
Devinsky, O., & Parra, L.C. (2017) Measurements and models of electric fields in the in
vivo human brain during transcranial electric stimulation. *Elife*, **6**, 1–26.

Ishihara, S. (1917) *Tests for Color-Blindness*. Tokyo, Handaya, Hongo Harukicho.

Johns, M.W. (1991) A new method for measuring daytime sleepiness: The Epworth sleepiness
scale. *Sleep*, **14**, 540–545.

Kampman, K.M., Volpicelli, J.R., Mcginnis, D.E., Alterman, A.I., Weinrieb, R.M., D'Angelo, L.,
& Epperson, L.E. (1998) Reliability and validity of the cocaine selective severity
assessment. *Addict. Behav.*, **23**, 449–461.

Kirby, K.N., Petry, N.M., & Bickel, W.K. (1999) Heroin addicts have higher discount rates for
delayed rewards than non-drug-using controls. *J. Exp. Psychol. Gen.*, **128**, 78–87.

Klauss, J., Anders, Q.S., Felippe, L.V., Buback Ferreira, L.V., Cruz, M.A., Nitsche, M.A., &
Nakamura-Palacios, E.M. (2018) Lack of effects of extended sessions of transcranial direct
current stimulation (tDCS) over dorsolateral prefrontal cortex on craving and relapses in
crack-cocaine users. *Front. Pharmacol.*, **9**, 1–11.

Kuo, M.F., Paulus, W., & Nitsche, M.A. (2014) Therapeutic effects of non-invasive brain
stimulation with direct currents (tDCS) in neuropsychiatric diseases. *Neuroimage*, **85**, 948–
960.

Lezak, M., Howieson, D., Bigler, E., & Tranel, D. (2012) *Neuropsychological Assessment*.
Oxford University Press, New York, Ny.

Liu, J. feng & Li, J. xu (2018) Drug addiction: a curable mental disorder? *Acta Pharmacol. Sin.*, **39**, 1823–1829.

López-Alonso, V., Cheeran, B., Río-Rodríguez, D., & Fernández-Del-Olmo, M. (2014) Inter-individual variability in response to non-invasive brain stimulation paradigms. *Brain Stimul.*, **7**, 372–380.

Lubman, D.I., Yücel, M., & Pantelis, C. (2004) Addiction, a condition of compulsive behaviour? Neuroimaging and neuropsychological evidence of inhibitory dysregulation. *Addiction*, **99**, 1491–1502.

Ludwig, A.M. & Wikler, A. (1974) "Craving" and relapse to drink. *Q. J. Stud. Alcohol*, **35**, 108–130.

Ma, T., Sun, Y., & Ku, Y. (2019) Effects of Non-invasive Brain Stimulation on Stimulant Craving in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-Analysis. *Front. Neurosci.*, **13**, 1–9.

Martinotti, G., Lupi, M., Montemitro, C., Miuli, A., Di Natale, C., Spano, M.C., Mancini, V., Lorusso, M., Stigliano, G., Tambelli, A., Di Carlo, F., Di Caprio, L., Fraticelli, S., Chillemi, E., Pettorruso, M., Sepede, G., & Di Giannantonio, M. (2019) Transcranial Direct Current Stimulation Reduces Craving in Substance Use Disorders: A Double-blind, Placebo-Controlled Study. *J. ECT*, **35**, 207–211.

McLellan, A.T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) The fifth edition of the addiction severity index. *J. Subst. Abuse Treat.*, **9**, 199–213.

Mejía-Cruz, D., Green, L., Myerson, J., Morales-Chainé, S., & Nieto, J. (2016) Delay and probability discounting by drug-dependent cocaine and marijuana users. *Psychopharmacology (Berl).*, **233**, 2705–2714.

Mellentin, A.I., Skøt, L., Nielsen, B., Schippers, G.M., Nielsen, A.S., Stenager, E., & Juhl, C. (2017) Cue exposure therapy for the treatment of alcohol use disorders: A meta-analytic review. *Clin. Psychol. Rev.*, **57**, 195–207.

Michalec, E.M., Rohsenow, D.J., Monti, P.M., Varney, S.M., Martin, R.A., Dey, A.N., Myers, M.G., & Sirota, A.D. (1996) A cocaine negative consequences checklist: development and validation. *J. Subst. Abuse*, **8**, 181–193.

Milenkovic, S. & Dragovic, M. (2013) Modification of the Edinburgh Handedness Inventory: A replication study. *Laterality*, **18**, 340–348.

Minichino, A., Bersani, F.S., Spagnoli, F., Corrado, A., De Michele, F., Calò, W.K., Primavera, M., Yang, B., Bernabei, L., Macrì, F., Vergnani, L., Biondi, M., & Delle Chiaie, R. (2014) Prefronto-cerebellar transcranial direct current stimulation improves sleep quality in euthymic bipolar patients: A brief report. *Behav. Neurol.*, **2014**.

Nakamura-Palacios, E.M., Lopes, I.B.C., Souza, R.A., Klauss, J., Batista, E.K., Conti, C.L., Moscon, J.A., & de Souza, R.S.M. (2016) Ventral medial prefrontal cortex (vmPFC) as a target of the dorsolateral prefrontal modulation by transcranial direct current stimulation (tDCS) in drug addiction. *J. Neural Transm.*, **123**, 1179–1194.

Nitsche, M.A. & Paulus, W. (2000) Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. *J. Physiol.*, **527**, 633–639.

Odum, A.L. (2011) Delay Discounting: I'M a K, You'Re a K. *J. Exp. Anal. Behav.*, **96**, 427–439.

Opitz, A., Legon, W., Rowlands, A., Bickel, W.K., Paulus, W., & Tyler, W.J. (2013) Physiological observations validate finite element models for estimating subject-specific electric field distributions induced by transcranial magnetic stimulation of the human motor cortex. *Neuroimage*, **81**, 253–264.

Opitz, A., Windhoff, M., Heidemann, R.M., Turner, R., & Thielscher, A. (2011) How the brain

tissue shapes the electric field induced by transcranial magnetic stimulation. *Neuroimage*, **58**, 849–859.

Opsal, A., Kristensen, Ø., & Clausen, T. (2019) Readiness to change among involuntarily and voluntarily admitted patients with substance use disorders. *Subst. Abus. Treat. Prev. Policy*, **14**, 1–10.

Pace-Schott, E.F. & Hobson, J.A. (2002) The neurobiology of sleep: Genetics, cellular physiology and subcortical networks. *Nat. Rev. Neurosci.*, **3**, 591–605.

Paliwal, P., Hyman, S.M., & Sinha, R. (2008) Craving predicts time to cocaine relapse: Further validation of the Now and Brief versions of the cocaine craving questionnaire. *Drug Alcohol Depend.*, **93**, 252–259.

Parvaz, M.A., Moeller, S.J., & Goldstein, R.Z. (2016) Incubation of cue-induced craving in adults addicted to cocaine measured by electroencephalography. *JAMA Psychiatry*, **73**, 1127–1134.

Pocock, S.J., Assmann, S.E., Enos, L.E., & Kasten, L.E. (2002) Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: Current practice and problems. *Stat. Med.*, **21**, 2917–2930.

Rapinesi, C., Bersani, F.S., Kotzalidis, G.D., Imperatori, C., Del Casale, A., Di Pietro, S., Ferri, V.R., Serata, D., Raccah, R.N., Zangen, A., Angeletti, G., & Girardi, P. (2015) Maintenance deep transcranial magnetic stimulation sessions are associated with reduced depressive relapses in patients with unipolar or bipolar depression. *Front. Neurol.*, **6**, 1–5.

Rapinesi, C., Del Casale, A., Di Pietro, S., Ferri, V.R., Piacentino, D., Sani, G., Raccah, R.N., Zangen, A., Ferracuti, S., Vento, A.E., Angeletti, G., Brugnoli, R., Kotzalidis, G.D., & Girardi, P. (2016) Add-on high frequency deep transcranial magnetic stimulation (dTMS) to bilateral prefrontal cortex reduces cocaine craving in patients with cocaine use disorder.

Neurosci. Lett., **629**, 43–47.

Ridding, M.C. & Ziemann, U. (2010) Determinants of the induction of cortical plasticity by non-invasive brain stimulation in healthy subjects. *J. Physiol.*, **588**, 2291–2304.

Rossi, S., Hallett, M., Rossini, P.M., Pascual-Leone, A., Avanzini, G., Bestmann, S., Berardelli, A., Brewer, C., Canli, T., Cantello, R., Chen, R., Classen, J., Demitrack, M., Di Lazzaro, V., Epstein, C.M., George, M.S., Fregni, F., Ilmoniemi, R., Jalinous, R., Karp, B., Lefaucheur, J.P., Lisanby, S., Meunier, S., Miniussi, C., Miranda, P., Padberg, F., Paulus, W., Peterchev, A., Porteri, C., Provost, M., Quartarone, A., Rotenberg, A., Rothwell, J., Ruohonen, J., Siebner, H., Thut, G., Valls-Solè, J., Walsh, V., Ugawa, Y., Zangen, A., & Ziemann, U. (2009) Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. *Clin. Neurophysiol.*, **120**, 2008–2039.

Sämann, P.G., Wehrle, R., Hoehn, D., Spoormaker, V.I., Peters, H., Tully, C., Holsboer, F., & Czisch, M. (2011) Development of the brain's default mode network from wakefulness to slow wave sleep. *Cereb. Cortex*, **21**, 2082–2093.

Sampaio-Junior, B., Tortella, G., Borrione, L., Moffa, A.H., Machado-Vieira, R., Cretaz, E., Da Silva, A.F., Fraguas, R., Aparício, L. V., Klein, I., Lafer, B., Goerigk, S., Benseñor, I.M., Lotufo, P.A., Gattaz, W.F., & Brunoni, A.R. (2018) Efficacy and safety of transcranial direct current stimulation as an add-on treatment for bipolar depression: A randomized clinical trial. *JAMA Psychiatry*, **75**, 158–166.

Santos, L., Martinho, M., Salvador, R., Wenger, C., Fernandes, S.R., Ripolles, O., Ruffini, G., & Miranda, P.C. (2016) Evaluation of the electric field in the brain during transcranial direct current stimulation: A sensitivity analysis. In *38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)*. IEEE, pp. 1778–1781.

Shahbabaie, A., Ebrahimpoor, M., Hariri, A., Nitsche, M.A., Hatami, J., Fatemizadeh, E.,

Oghabian, M.A., & Ekhtiari, H. (2018) Transcranial DC stimulation modifies functional
connectivity of large-scale brain networks in abstinent methamphetamine users. *Brain
Behav.*, **8**, 1–13.

Shahbabaie, A., Golesorkhi, M., Zamanian, B., Ebrahimpoor, M., Keshvari, F., Nejati, V.,
Fregni, F., & Ekhtiari, H. (2014) State dependent effect of transcranial direct current
stimulation (tDCS) on methamphetamine craving. *Int. J. Neuropsychopharmacol.*, **17**,
1591–1598.

Sheng, J., Xie, C., Fan, D. qiong, Lei, X., & Yu, J. (2018) High definition-transcranial direct
current stimulation changes older adults' subjective sleep and corresponding resting-state
functional connectivity. *Int. J. Psychophysiol.*, **129**, 1–8.

Simon, N.W., Mendez, I.A., & Setlow, B. (2007) Cocaine exposure causes long-term increases in
impulsive choice. *Behav. Neurosci.*, **121**, 543–549.

Skevington, S.M., Lotfy, M., & O'Connell, K. a. (2004) The World Health Organization's
WHOQOL-BREF quality of life assessment: Psychometric properties and results of the
international field trial. A Report from the WHOQOL Group. *Qual. Life Res.*, **13**, 299–310.

Sofuoglu, M. & Kosten, T.R. (2006) Emerging pharmacological strategies in the fight against
cocaine addiction. *Expert Opin. Emerg. Drugs*, **11**, 91–98.

Terraneo, A., Leggio, L., Saladini, M., Ermani, M., Bonci, A., & Gallimberti, L. (2016)
Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: A
pilot study. *Eur. Neuropsychopharmacol.*, **26**, 37–44.

Tiffany, S.T., Friedman, L., Greenfield, S.F., Hasin, D.S., & Jackson, R. (2012) Beyond drug
use: a systematic consideration of other outcomes in evaluations of treatments for substance
use disorders. *Addiction*, **107**, 709–718.

Tiffany, S.T., Singleton, E., Haertzen, C.A., & Henningfield, J.E. (1993) The development of a

cocaine craving questionnaire. *Drug Alcohol Depend.*, **34**, 19–28.

Tiffany, S.T. & Wray, J.M. (2012) The clinical significance of drug craving. *Ann. N. Y. Acad. Sci.*, **1248**, 1–17.

Volkow, N.D. & Fowler, J.S. (2000) Addiction, a Disease of Compulsion and Drive: Involvement of the Orbitofrontal Cortex. *Cereb. Cortex*, **10**, 318–325.

Volkow, N.D., Wang, G.J., Fowler, J.S., Tomasi, D., Telang, F., & Baler, R. (2010) Addiction: Decreased reward sensitivity and increased expectation sensitivity conspire to overwhelm the brain's control circuit. *BioEssays*, **32**, 748–755.

Vorspan, F., Bellais, L., Romo, L., Bloch, V., Neira, R., & Lépine, J.P. (2012) The Obsessive-Compulsive Cocaine Scale (OCCS): A pilot study of a new questionnaire for assessing cocaine craving. *Am. J. Addict.*, **21**, 313–319.

Wagner, T., Valero-Cabre, A., & Pascual-Leone, A. (2007) Noninvasive Human Brain Stimulation. *Annu. Rev. Biomed. Eng.*, **9**, 527–565.

Watson, D., Clark, L.A., & Tellegen, A. (1988) Development and validation of brief measures of positive and negative affect: The PANAS scales. *J. Pers. Soc. Psychol.*, **54**, 1063–1070.

Wechsler, D. (1999) *Wechsler Abbreviated Scale of Intelligence*. Psychological Corporation, San Antonio, TX.

Weiss, R.D., Griffin, M.L., Mazurick, C., Berkman, B., Gastfriend, D.R., Frank, A., Barber, J.P., Blaine, J., Salloum, I., & Moras, K. (2003) The Relationship Between Cocaine Craving, Psychosocial Treatment, and Subsequent Cocaine Use. *Am. J. Psychiatry*, **160**, 1320–1325.

Wiegand, A., Sommer, A., Nieratschker, V., & Plewnia, C. (2019) Improvement of cognitive control and stabilization of affect by prefrontal transcranial direct current stimulation (tDCS). *Sci. Rep.*, **9**, 1–8.

Wilkinson, G.S. (1993) *Wide Range Achievement Test 3*. Wide Range, Inc, Wilmington, DE.

Woods, A.J., Antal, A., Bikson, M., Boggio, P.S., Brunoni, A.R., Celnik, P., Cohen, L.G., Fregni,

F., Herrmann, C.S., Kappenman, E.S., Knotkova, H., Liebetanz, D., Miniussi, C., Miranda,

P.C., Paulus, W., Priori, A., Reato, D., Stagg, C., Wenderoth, N., & Nitsche, M.A. (2016) A

technical guide to tDCS, and related non-invasive brain stimulation tools. *Clin.*

Neurophysiol., **127**, 1031–1048.

Zilverstand, A., Parvaz, M.A., Moeller, S.J., & Goldstein, R.Z. (2016) *Cognitive Interventions for*

Addiction Medicine: Understanding the Underlying Neurobiological Mechanisms, 1st edn,

Progress in Brain Research. Elsevier B.V.

A. 5-item OCCS craving subscale


**B.** 5-item Cocaine Craving Questionnaire


C. Craving Intensity Item - CSSA

A. Epworth Sleepiness Scale

B. Contemplation Ladder

Table 1 – Demographic, neuropsychological, clinical drug use, and outcome measures in sham- and real-tDCS groups.

	Sham-tDCS (N = 6)		Real-tDCS (N = 8)		Main effects (Cohen's *d*)		
	Pre-sham	Post-sham	Pre-tDCS	Post-tDCS	Group	Time	Interaction
Demographics							
Age (years)	46.7 ± 13.9	--	40.4 ± 10.2	--	t_{12} = 1.0	N/A	N/A
Sex (male/female)	6 / 0	--	6 / 2	--	χ^2 = 1.8	N/A	N/A
Race (African-American/Caucasian/ Mixed)	3 / 3 / 0	--	1 / 6 / 1	--	χ^2 = 2.8	N/A	N/A
Ethnicity (Hispanic/Non-Hispanic)	2 / 4	--	3 / 5	--	χ^2 = 0.0	N/A	N/A
Education (years)	11.1 ± 1.4	--	12.3 ± 2.6	--	t_{12} = -1.0	N/A	N/A
Handedness (Right/Left/Ambidextrous)	6 / 0 / 0	--	6 / 0 / 1[a]	--	χ^2 = 0.9	N/A	N/A
Neuropsychological tests							
WRAT – Reading Scale (standard score)	98.5 ± 13.5	--	92.0 ± 10.3[a]	--	t_{11} = 1.0	N/A	N/A
WASI – Matrix Reasoning (scaled score)	9.8 ± 3.3	--	9.0 ± 2.0[a]	--	t_{11} = 0.6	N/A	N/A
Semantic (neutral) verbal fluency	17.6 ± 2.0	20.3 ± 1.5	18.0 ± 1.7	17.8 ± 1.3	F = 0.3 (*d* = .30)	F = 1.3 (*d* = .64)	F = 1.6 (*d* = .74)
Drug verbal fluency	16.8 ± 1.9	17.0 ± 1.6	16.8 ± 1.6	17.1 ± 1.4	F = 0.0 (*d* = .00)	F = 0.2 (*d* = .24)	F = 0.0 (*d* = .09)
Kirby delay discounting task	0.13 ± 0.04	0.07 ± 0.02	0.12 ± 0.03	0.06 ± 0.01	F = 0.2 (*d* = .24)	**F = 5.7 (*d* = 1.4)***	F = 0.0 (*d* = .10)
Clinical drug use measures							
Cocaine use lifetime (years)	14.3 ± 9.0	--	8.1 ± 7.6	--	t_{12} = 1.4	N/A	N/A
Duration of current abstinence (days)	46.2 ± 13.4	77.0 ± 15.4	59.4 ± 11.6	84.6 ± 13.3	F = 0.3 (*d* = .33)	**F = 31.5 (*d* = 3.2)***	F = 0.3 (*d* = .32)
Severity of dependence scale	10.8 ± 3.3	--	11.0 ± 2.4	--	t_{12} = -0.1	N/A	N/A
Cocaine selective severity assessment	17.8 ± 5.0	20.3 ± 5.3	14.9 ± 4.4	9.0 ± 4.6	F = 1.4 (*d* = .68)	F = 0.3 (*d* = .30)	F = 1.7 (*d* = .75)
Cocaine negative consequences checklist	43.3 ± 6.2	49.2 ± 6.1	30.9 ± 5.4	29.3 ± 5.3	**F = 6.5 (*d* = 1.5)***	F = 0.2 (*d* = .24)	F = 0.5 (*d* = .42)
Primary outcome measures							
5-item OCCS craving subscale	5.5 ± 1.6	5.8 ± 1.5	4.4 ± 1.3	1.6 ± 1.3	F = 3.1 (*d* =1.0)	F = 0.9 (*d* =.53)	F = 1.4 (*d* = .68)
5-item cocaine cravings	14.2 ± 4.6	7.3 ± 3.5	11.1 ± 4.0	6.9 ± 3.0	F = 0.1 (*d* = .22)	**F = 4.2 (*d* = 1.2)[†]**	F = 0.2 (*d* = .28)
Hamilton anxiety rating scale	8.0 ± 3.4	9.3 ± 3.8	6.5 ± 2.9	5.3 ± 3.3	F = 0.5 (*d* = .40)	F = 0.0 (*d* = .00)	F = 0.3 (*d* = .30)
Hamilton depression rating scale	8.5 ± 4.0	4.8 ± 1.8	5.6 ± 3.4	3.3 ± 1.6	F = 0.4 (*d* = .38)	F = 1.9 (*d* = .79)	F = 0.1 (*d* = .17)
Quality of life – Physical health	15.2 ± 1.2	16.7 ± 1.2	15.5 ± 1.1	16.1 ± 1.0	F = 0.0 (*d* = .04)	F = 2.0 (*d* = .82)	F = 0.4 (*d* = .34)
Quality of life – Psychological	15.3 ± 1.4	15.8 ± 1.2	15.5 ± 1.2	16.8 ± 1.0	F = 0.1 (*d* = .22)	F = 1.1 (*d* = .61)	F = 0.2 (*d* = .26)
Quality of life – Social relationship	11.8 ± 1.8	13.2 ± 0.9	12.6 ± 1.5	12.1 ± 0.8	F = 0.0 (*d* = .05)	F = 0.1 (*d* = .21)	F = 0.6 (*d* = .45)
Quality of life – Environment	12.7 ± 1.0	15.2 ± 1.2	12.4 ± 0.9	13.6 ± 1.0	F = 0.5 (*d* = .39)	**F = 10.9 (*d* = 1.9)***	F = 1.2 (*d* = .64)
Secondary outcome measures							
Epworth sleepiness scale	7.8 ± 1.8[b]	11.0 ± 1.7	7.1 ± 1.4	5.1 ± 1.3	F = 3.1 (*d* = 1.1)	F = 0.3 (*d* = .32)	**F = 5.2 (*d* = 1.4)***
Pittsburgh sleep quality index	7.4 ± 1.7[b]	8.2 ± 2.0	3.9 ± 1.3	6.0 ± 1.6	F = 1.6 (*d* = .76)	**F = 5.0 (*d* = 1.4)***	F = 1.0 (*d* = .61)
Contemplation ladder	8.7 ± 0.5	8.3 ± 0.6	8.0 ± 0.4	9.1 ± 0.5	F = 0.0 (*d* = .06)	F = 1.6 (*d* = .73)	**F = 5.4 (*d* = 1.3)***
PANAS – Positive affect	38.7 ± 2.9	41.3 ± 2.5	41.5 ± 2.5	40.3 ± 2.2	F = 0.1 (*d* = .16)	F = 0.2 (*d* = .26)	F = 1.6 (*d* = .73)
PANAS – Negative affect	19.8 ± 3.6	21.7 ± 3.6	17.8 ± 3.1	16.9 ± 3.1	F = 0.6 (*d* = .44)	F = 0.1 (*d* = .21)	F = 1.0 (*d* = .59)

Notes: Data expressed as frequencies or means ± standard deviation (SD). [a]One datapoint was missing for two participants, one for WRAT – Reading scale and one for the WASI – Matrix score and handedness. [b]One participant was also missing the pre-tDCS sleepiness questionnaires. OCCS: Obsessive-Compulsive Cocaine Scale PANAS: Positive and Negative Affect Schedule; WASI: Wechsler Abbreviated Scale of Intelligence; WRAT: Wide Range Achievement Test. [†]trend at $p < 0.1$; *$p < 0.05$; **$p < 0.01$.

Table 2 – Follow-up analyses of outcome measures showing a significant effect of tDCS treatment (Time or Time by Group) in sham- and real-tDCS groups

	Sham-tDCS (N = 5)			Real-tDCS (N = 7)			Main effects p values		
	Pre-Sham	Post-Sham	Follow-Up	Pre-tDCS	Post-tDCS	Follow-Up	Group	Time	Interaction
Primary outcome measures									
5-item OCCS craving subscale	5.2 ± 1.9	6.6 ± 1.7	6.4 ± 1.9	4.4 ± 1.6	1.9 ± 1.4	2.4 ± 1.6	p = .119	p = .895	p = .276
5-item cocaine cravings	14.8 ± 5.3	8.2 ± 4.1	13.0 ± 6.3	12.7 ± 4.5	6.9 ± 3.5	12.4 ± 5.3	p = .825	p = .147	p = .973
Quality of life – Environment	12.6 ± 1.0	15.0 ± 1.3	16.0 ± 1.1	13.0 ± 0.8	14.1 ± 1.1	13.9 ± 0.9	p = .517	**p = .011**	p = .195
Secondary outcome measures									
Epworth sleepiness scale	8.3 ± 2.2	11.8 ± 1.8	10.5 ± 1.8	7.4 ± 1.6	4.4 ± 1.3	8.9 ± 1.4	p = .154	p = .178	**p = .011**
Pittsburgh sleep quality index	7.8 ± 1.9	8.3 ± 2.0	6.0 ± 1.6	3.3 ± 1.5	4.7 ± 1.5	5.0 ± 1.2	p = .172	p = .506	p = .193
Contemplation ladder	8.4 ± 0.5	8.0 ± 0.7	9.0 ± 0.4	7.9 ± 0.5	9.1 ± 0.6	8.7 ± 0.4	p = .826	p = .327	p = .210

Notes: Data expressed as means ± standard deviation (SD). One participant was missing the pre-tDCS sleepiness questionnaires. OCCS: Obsessive-Compulsive Cocaine Scale.

Table 3 – Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) measures in sham- and real-tDCS groups.

Reward	Situation	Question	Sham-tDCS (N = 6)		Real-tDCS (N = 8)	
			Pre-sham	Post-sham	Pre-tDCS	Post-tDCS
Food	Currently	Liking	4.5 ± 0.5	4.7 ± 0.8	3.9 ± 1.6	4.4 ± 0.9
		Wanting	3.8 ± 1.5	4.3 ± 1.2	3.8 ± 1.6	3.4 ± 1.4
	In General	Liking	4.3 ± 0.8	5.0 ± 0.0	4.0 ± 0.9	4.3 ± 0.9
		Wanting	3.2 ± 0.4	4.7 ± 0.5	4.0 ± 0.9	4.3 ± 1.2
	Under the influence/high	Liking	2.7 ± 1.9	4.0 ± 1.7	2.9 ± 1.9	2.9 ± 1.8
		Wanting	2.7 ± 1.9	3.2 ± 1.6	3.1 ± 2.0	2.9 ± 2.0
Sexual Activity	Currently	Liking	4.8 ± 0.4	5.0 ± 0.0	3.8 ± 1.2	3.8 ± 1.8
		Wanting	4.5 ± 1.2	4.8 ± 0.4	3.3 ± 1.6	3.5 ± 1.9
	In General	Liking	4.8 ± 0.4	4.8 ± 0.4	4.0 ± 1.1	4.1 ± 1.5
		Wanting	4.7 ± 0.8	4.7 ± 0.8	3.3 ± 1.4	3.4 ± 1.5
	Under the influence/high	Liking	4.7 ± 0.8	3.8 ± 1.6	2.9 ± 1.6	3.6 ± 1.8
		Wanting	4.7 ± 0.8	4.0 ± 1.5	2.5 ± 1.3	3.6 ± 1.7
Drug	Currently	Liking	2.0 ± 1.7	2.7 ± 1.6	2.1 ± 1.4	2.0 ± 1.6
		Wanting	1.5 ± 0.8	1.2 ± 0.4	1.4 ± 0.5	1.4 ± 0.7
	In General	Liking	3.0 ± 1.3	2.2 ± 1.6	3.1 ± 1.6	2.6 ± 1.8
		Wanting	2.5 ± 1.8	1.5 ± 0.8	1.5 ± 0.5	1.9 ± 1.5
	Under the influence/high	Liking	3.8 ± 1.0	2.7 ± 1.2	2.8 ± 1.6	3.0 ± 1.5
		Wanting	4.3 ± 0.8	4.0 ± 1.3	3.6 ± 1.8	4.0 ± 1.4

Significant Statistical Effects

Reward Effect	Question Effect	--------------------- Group Effect ---------------------
$(p < 0.0001)$	$(p < 0.01)$	$(p < 0.01)$

Reward × Situation Interaction
$(p < 0.0001)$

Situation × Question Interaction
$(p < 0.001)$

Reward × Situation × Question Interaction
$(p < 0.01)$

Notes: Data expressed as means ± standard deviation (SD). STRAP-R values represent the rating on a Likert scale ranging from "Somewhat" (1) to "Extremely (5)."